King Of Hearts: Testosterone Protects Older Men From Cardiovascular Disease & Stroke

Evidence that high testosterone can be a potential lifesaver for us guys just keeps coming it seems as now a research team in the U.S has declared that supplementation of the male hormone in vulnerable older men can hugely decrease the probability of heart attack and stroke.

This is a reversal of what was once widely believed and should ease fears that strong T is a contributor to these deadly conditions.

Scientists from the Intermountain Medical Centre Heart Institute in Salt Lake City, Utah, studied 755 heart patients aged between 58 and 78, some of whom were given supplements of the male hormone that was injected or administered in a gel. This treatment was found to cut subjects’ risk by a massive 80%.

Lead scientist Dr Brent Muhlestein and his colleagues found that after a period of one year, 64 participants who had not been bolstered with testosterone suffered a major cardiac incident, compared to just 12 who were given medium levels of hormone enhancement and just 9 who were on the highest dose.

These findings were reinforced two years later, by which point a total of 125 patients who had gone without additional male hormone had experienced a serious health event, against just 38 on the medium supplementation and 22 on the high.

Testosterone levels are known to begin gradually decreasing from the age 30 and beyond by about 1% per year, therefore by the time we reach the age range of this trial group most of us will have a considerable hormonal shortfall and, as this study demonstrates, are likely to be more susceptible to what remain two of the biggest killers among men of an older age.

Dr Muhlestein said of the findings;

“The study shows that increasing testosterone to normal levels in androgen-deficient men doesn’t increase their risk of a serious heart attack or stroke.”

Commenting on the FDA’s call last year for labelling of testosterone products outlining what was once believed to be the possible dangers, Muhlestein continued,

“The FDA’s warning was based on the best clinical information available at the time. As further information, like our research, becomes available – and especially after a large randomised clinical outcomes trial can be accomplished – hopefully the FDA will be able to change its warning.”

The above findings were presented at the American College of Cardiology’s 65th annual scientific session in Chicago.

Write a comment